ANI Pharmaceuticals, Inc. (ANIP) Fair Value 2026

ANIP · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.0 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-27, ANI Pharmaceuticals, Inc. (ANIP) trades at $73.51, versus a $94.16 median fair value across its 9 active models — 28.1% above the current price. QOC: 9.0/10. Value Trap Risk: 18/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $37.41.

Key Facts

Ticker
ANIP
Price
$73.51
Quality Score
9.0/10
Value Trap Risk
18/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +119.5% upside with 59% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is ANI Pharmaceuticals, Inc. (ANIP) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, ANI Pharmaceuticals, Inc. (ANIP) appears undervalued as of : the median of 9 independent fair value estimates is $94.16, 28.1% above the current price of $73.51. Estimates range from $37.41 to $231.85. ANIP scores 9.0/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ANIP’s +28.1% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy ANI Pharmaceuticals, Inc. Stock in 2026? →

What Fair Value Does Each Model Give ANIP?

9 Intrinsic Value Models vs. Current Price ($73.51)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $37.41 -49.1%
Ensemble · Low Conviction
 $92.53 +25.9%
Scenario · High Conviction
 $161.35 +119.5%
Intrinsic · High Conviction
 $59.48 -19.1%
Unlock the Full Matrix

Access 5 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is ANIP's Fair Value Range?

Spread across 9 independent models · $37.41 to $231.85

CirclFi's 9 active models place ANI Pharmaceuticals, Inc. (ANIP) between $37.41 and $231.85 per share, a spread of 206% of the median. The median of that range — $94.16 — is the fair value CirclFi publishes for ANIP, against a current price of $73.51.

Low · Bayesian DCFHigh · Regime Cross
$37.41median $94.16$231.85
Where the range comes from
Most bearish modelBayesian DCF$37.41
Most bullish modelRegime Cross-Sectional$231.85
Model agreement6 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ANIP. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ANIP, not a CirclFi price target. How each model works →

What Is ANI Pharmaceuticals, Inc. (ANIP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ANI Pharmaceuticals, Inc.'s intrinsic value is estimated at $94.16, suggesting a +28.1% median upside from the current price of $73.51. While 6 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: Regime Cross targets $231.85 (+215.4%), versus Bayesian DCF at $37.41 (-49.1%). This +264.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ANIP?

9 of 13 models are currently active for ANIP. Of these, 6 models suggest upside while 3 models suggest overvaluation. Taken together, their median fair value for ANIP is $94.16 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $37.41 on its own, implying -49.1% downside from the current price. See which stocks rank higher →

How Does ANIP Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, ANIP ranks #6 by Quality of Company score. CirclFi's QOC score of 9.0/10 evaluates 32 fundamental signals. A score of 9.0 places ANIP in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

ANI Pharmaceuticals, Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is ANIP a Value Trap?

CirclFi's Value Trap algorithm assigns ANIP a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for ANI Pharmaceuticals, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, ANI Pharmaceuticals, Inc. earns a quality score of 9.0/10. This exceptional rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +264.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ANIP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ANIP's 9 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ANI Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

NBIXNeurocrine Biosciences, Inc.QOC 9.1ELTPElite Pharmaceuticals, Inc.QOC 8.8LNTHLantheus Holdings, Inc.QOC 9.3RDYDr. Reddy's Laboratories LimitedQOC 8.8ZTSZoetis Inc.QOC 9.3COLLCollegium Pharmaceutical, Inc.QOC 8.8HROWHarrow, Inc.QOC 7.0LFCRLifecore Biomedical, Inc.QOC 5.9CPMDCannaPharmaRX, Inc.QOC 4.6UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: NBIX · ELTP · LNTH · RDY · ZTS · COLL · HROW · LFCR · CPMD · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to ANIP?

7 companies across all industries closest to ANIP’s Quality of Company score of 9.0/10.

AOSA. O. Smith CorporationQOC 9.0AWIArmstrong World Industries, Inc.QOC 9.0HAYWHayward Holdings, Inc.QOC 9.0ALVAutoliv, Inc.QOC 9.0FDSFactSet Research Systems Inc.QOC 9.0VMIValmont Industries, Inc.QOC 9.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AOS · AWI · HAYW · ALV · FDS · VMI · NVDA

Where Does ANIP Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

ANIP is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About ANI Pharmaceuticals, Inc.’s Valuation?

What is ANI Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi puts ANI Pharmaceuticals, Inc. (ANIP)'s intrinsic value at $94.16 — the median of 9 independent model estimates as of 2026-08-27, ranging from $37.41 to $231.85. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $37.41 on its own. The Quality of Company score is 9.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ANIP overvalued or undervalued right now?

At $73.51, 6 of 9 active models suggest ANIP may be undervalued, while 3 indicate potential overvaluation. The median of all 9 fair value estimates is $94.16, 28.1% above the current price of $73.51 — a consensus view that ANIP is undervalued. The assessment depends on which methodology best fits ANI Pharmaceuticals, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 9.0 mean for ANIP?

ANI Pharmaceuticals, Inc.'s QOC of 9.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ANIP?

CirclFi analyzes ANIP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ANIP?

Of the 9 models currently active on ANIP, Regime Cross-Sectional is the most bullish at $231.85 per share, and Bayesian DCF is the most bearish at $37.41. CirclFi's published fair value for ANIP is the median of that range, $94.16, not either extreme. The gap between the two ends equals 206% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ANIP a value trap in 2026?

ANI Pharmaceuticals, Inc.'s Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, ANI Pharmaceuticals, Inc. (ANIP) has a median fair value of $94.16 — 28.1% above the current price of $73.51 — as of 2026-08-27.” Source: circlfi.com/stock/ANIP/ · Methodology
Primary sources for this ANIP valuation
  • Financial statements: ANI Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001023024) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ANIP as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on ANIP.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for ANIP Unlock All 9 — $39/mo